What Happens When Imatinib Goes Generic?

被引：7

作者：

McDougall, Jean ^{[1
,2
]}

Ramsey, Scott D. ^{[3
,4
,5
,6
]}

Radich, Jerald ^{[7
,8
,9
,10
,11
]}

机构：

[1] Univ Washington, Pharmaceut Outcomes Res & Policy Program, Seattle, WA 98195 USA

[2] Fred Hutchinson Canc Res Ctr, Hutchinson Inst Canc Outcomes Res, Div Publ Hlth Sci, 1124 Columbia St, Seattle, WA 98104 USA

[3] Univ Washington, Sch Pharm, Sch Med, Seattle, WA 98195 USA

[4] Univ Washington, Inst Publ Hlth Genet, Seattle, WA 98195 USA

[5] Southwest Oncol Grp, Outcomes & Comparat Effectiveness Comm, Seattle, WA USA

[6] ISPOR, Washington, DC USA

[7] Fred Hutchinson Canc Res Ctr, Mol Oncol Lab, Seattle, WA 98104 USA

[8] Southwest Oncol Grp, Leukemia Translat Med Comm, Seattle, WA USA

[9] NCI, NIH, Leukemia Steering Comm, Bethesda, MD 20892 USA

[10] NIH, Genome Res Inst, Bethesda, MD USA

[11] NCCN Chron Myelogenous Leukemia CML Panel, New York, NY USA

来源：

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK | 2016年 / 14卷 / 02期

关键词：

CHRONIC MYELOID-LEUKEMIA; TYROSINE KINASE INHIBITORS; 24-MONTH FOLLOW-UP; DASATINIB; INTERFERON; RESISTANCE; BOSUTINIB; NILOTINIB; EFFICACY; SAFETY;

D O I：

10.6004/jnccn.2016.0016

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：128 / 131

页数：4

共 50 条